Comparative study between the therapeutic effect of remdesivir versus hydroxychloroquine in COVID-19 hospitalized patients
et al., Microbes and Infectious Diseases, doi:10.21608/mid.2021.85877.1177, Aug 2021
Small study comparing 25 HCQ and 25 remdesivir hospitalized patients, reporting faster viral clearance with remdesivir. The article proof is missing the results for the HCQ group. Confounding by time is likely - remdesivir patients were after HCQ patients in time, and treatment protocols improved over the period of the study.
Gérard, Zhou, Wu, Kamo, Choi, Kim show increased risk of acute kidney injury, Leo, Briciu, Muntean, Petrov show increased risk of liver injury, and Negru, Cheng, Mohammed show increased risk of cardiac disorders with remdesivir.
Study covers remdesivir and HCQ.
1.
Gérard et al., Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.2145.
2.
Zhou et al., Acute Kidney Injury and Drugs Prescribed for COVID-19 in Diabetes Patients: A Real-World Disproportionality Analysis, Frontiers in Pharmacology, doi:10.3389/fphar.2022.833679.
3.
Wu et al., Acute Kidney Injury Associated With Remdesivir: A Comprehensive Pharmacovigilance Analysis of COVID-19 Reports in FAERS, Frontiers in Pharmacology, doi:10.3389/fphar.2022.692828.
4.
Kamo et al., Association of Antiviral Drugs for the Treatment of COVID-19 With Acute Renal Failure, In Vivo, doi:10.21873/invivo.13637.
5.
Choi et al., Comparative effectiveness of combination therapy with nirmatrelvir–ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir–ritonavir in patients hospitalised with COVID-19: a target trial emulation study, The Lancet Infectious Diseases, doi:10.1016/S1473-3099(24)00353-0.
6.
Kim et al., Investigating the Safety Profile of Fast‐Track COVID‐19 Drugs Using the FDA Adverse Event Reporting System Database: A Comparative Observational Study, Pharmacoepidemiology and Drug Safety, doi:10.1002/pds.70043.
7.
Leo et al., Hepatocellular liver injury in hospitalized patients affected by COVID-19: Presence of different risk factors at different time points, Digestive and Liver Disease, doi:10.1016/j.dld.2021.12.014.
8.
Briciu et al., Evolving Clinical Manifestations and Outcomes in COVID-19 Patients: A Comparative Analysis of SARS-CoV-2 Variant Waves in a Romanian Hospital Setting, Pathogens, doi:10.3390/pathogens12121453.
9.
Muntean et al., Effects of COVID-19 on the Liver and Mortality in Patients with SARS-CoV-2 Pneumonia Caused by Delta and Non-Delta Variants: An Analysis in a Single Centre, Pharmaceuticals, doi:10.3390/ph17010003.
10.
Petrov et al., The Effect of Potentially Hepatotoxic Medicinal Products on Alanine Transaminase Levels in COVID-19 Patients: A Case–Control Study, Safety and Risk of Pharmacotherapy, doi:10.30895/2312-7821-2025-458.
11.
Negru et al., Comparative Pharmacovigilance Analysis of Approved and Repurposed Antivirals for COVID-19: Insights from EudraVigilance Data, Biomedicines, doi:10.3390/biomedicines13061387.
Eldeen et al., 16 Aug 2021, peer-reviewed, 5 authors.
Comparative study between the therapeutic effect of Remdesivir versus Hydroxychloroquine in Covid-19 hospitalized patients.
Microbes and Infectious Diseases, doi:10.21608/mid.2021.85877.1177
announced infections and about 4000 deaths were reported in more than 100 countries [1, 2] . In Egypt, the officially reported COVID-19 confirmed cases were 94,316 with 4,834 deaths on August 2020 [3] .
Conflict of interest: no conflict of interest.
Authors' Contribution All authors contributed equally to this work.
Financial disclosure This study was done as a part of the outbreak investigation conducted at Tanta University Hospitals, Egypt and supported by the Ministry of Higher Education (MHE). Patients with laboratory-confirmed SARS-CoV-2 infection, who were admitted to Tanta University Isolation Hospital ICU between June and September, 2020 were included.
Shankar
References
-Ali, Ali, Ahmed, Wy, Characteristics, and predictive factors of disease severity in hospitalized patients with SARS-COV-2 in Fayoum governorate, Egypt: a multicenter study, Microbes and Infectious Diseases
-Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention, Jama
-Yang, Islam, Wang, Li, Chen, Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective, International journal of biological sciences
Abena, Decloedt, Bottieau, Suleman, Adejumo et al., Chloroquine and hydroxychloroquine for the prevention or treatment of COVID-19 in Africa: caution for inappropriate off-label use in healthcare settings, The American journal of tropical medicine and hygiene
Corman, Landt, Kaiser, Molenkamp, Meijer et al., Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR, Eurosurveillance
Devaux, Rolain, Colson, Raoult, None
Nas, Ali, Azu, Abdallah, Yusuf, Epidemiology of novel COVID-19 in Nigeria, Microbes and Infectious Diseases
DOI record:
{
"DOI": "10.21608/mid.2021.85877.1177",
"ISSN": [
"2682-4140"
],
"URL": "http://dx.doi.org/10.21608/mid.2021.85877.1177",
"author": [
{
"affiliation": [],
"family": "Shams Eldeen",
"given": "Maii",
"sequence": "first"
},
{
"affiliation": [],
"family": "Abdelghafar",
"given": "Mohamed",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Ibrahim",
"given": "Hoda",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Aboalsoud",
"given": "Alshimaa",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Taha",
"given": "Marwa",
"sequence": "additional"
}
],
"container-title": "Microbes and Infectious Diseases",
"container-title-short": "Microbes and Infectious Diseases",
"content-domain": {
"crossmark-restriction": false,
"domain": [
"mid.journals.ekb.eg"
]
},
"created": {
"date-parts": [
[
2021,
9,
1
]
],
"date-time": "2021-09-01T19:38:30Z",
"timestamp": 1630525110000
},
"deposited": {
"date-parts": [
[
2021,
9,
1
]
],
"date-time": "2021-09-01T19:56:02Z",
"timestamp": 1630526162000
},
"indexed": {
"date-parts": [
[
2022,
4,
1
]
],
"date-time": "2022-04-01T15:36:25Z",
"timestamp": 1648827385494
},
"is-referenced-by-count": 0,
"issue": "0",
"issued": {
"date-parts": [
[
2021,
8,
16
]
]
},
"journal-issue": {
"issue": "0",
"published-online": {
"date-parts": [
[
2021,
8,
16
]
]
},
"published-print": {
"date-parts": [
[
2021,
8,
16
]
]
}
},
"language": "en",
"link": [
{
"URL": "https://mid.journals.ekb.eg/article_189643_d41d8cd98f00b204e9800998ecf8427e.pdf",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "9060",
"original-title": [],
"page": "0-0",
"prefix": "10.21608",
"published": {
"date-parts": [
[
2021,
8,
16
]
]
},
"published-online": {
"date-parts": [
[
2021,
8,
16
]
]
},
"published-print": {
"date-parts": [
[
2021,
8,
16
]
]
},
"publisher": "Egypts Presidential Specialized Council for Education and Scientific Research",
"reference-count": 0,
"references-count": 0,
"relation": {},
"resource": {
"primary": {
"URL": "https://mid.journals.ekb.eg/article_189643.html"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "Comparative study between the therapeutic effect of Remdesivir versus Hydroxychloroquine in Covid-19 hospitalized patients.",
"type": "journal-article",
"update-policy": "http://dx.doi.org/10.21608/crossmark_policy",
"volume": "0"
}
Late treatment
is less effective
is less effective
